Eyecare demand rises as aging population drives chronic needs

The global market for preservative-free eye drops is on a growth trajectory, driven by rising awareness of the long-term risks of chemical preservatives and a surge in chronic eye conditions.

According to new data from The Insight Partners, the sector is projected to reach $1.67 billion by 2031, up from $1.21 billion in 2024. That represents a compound annual growth rate of 4.3%.

Age-related disorders such as glaucoma, cataracts and macular degeneration are becoming more common, with the global population over 60 expected to double by 2050. These conditions often require lifelong treatment with topical eye medications. But traditional formulations containing preservatives like benzalkonium chloride (BAK) can exacerbate inflammation and irritation—especially for older patients with fragile tear films and slower ocular recovery.